News 2020-03-16
Porton Announces Opening of US Technology Center.
Chongqing, China--Porton announced the establishment of Porton U.S.A, LLC, a new subsidiary and Process Innovation Center located in Cranbury, New Jersey (NJ), United States. Deploying state-of-the-art laboratories and some of the industry’s most capable and experienced scientists, Porton’s NJ Center will provide our customers with impactful solutions to complex process challenges, next generation process development, gram to kilogram cGMP syntheses of specialized pharmaceutical intermediates and APIs including highly potent APIs and antibody drug conjugates, etc. Through flexibly structured, yet close-knit collaborations and geographical proximity, Porton’s NJ Center will bring new efficiencies to pharmaceutical development and lifecycle management for our valued global customers.
Others
More
News 2024-10-31
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Recently, Porton Pharma has achieved a significant capacity breakthrough at its GMP manufacturing facility in Fengxian, Shanghai, China, further enhancing its production capabilities and technological strength in new modality areas such as peptide and oligonucleotide drugs. This upgrade represents an important step in Porton's commitment to becoming a leading global CDMO company.
News 2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
On October 24, 2024, Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.
